Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Net-Income-Including-Non-Controlling-Interests" stands at 14.38 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2022.
Novartis AG's third quarter result of 3.93 Billion USD for the item "Net Income Including Non Controlling Interests" represents a decrease of -2.34 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 3.93 Billion USD for the item "Net Income Including Non Controlling Interests" represents an increase of 23.39 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 14.38 Billion USD for the item "Net Income Including Non Controlling Interests" represents an increase of 5.46 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 22.34 percent compared to the value the year prior.
The 1 year change in percent is 22.34.
The 3 year change in percent is -32.99.
The 5 year change in percent is 102.55.
The 10 year change in percent is 70.78.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income Including Non Controlling Interests | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Income Including Non Controlling Interests | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Income Including Non Controlling Interests | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income Including Non Controlling Interests | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Income Including Non Controlling Interests | 280,205,508,085.11 |